Literature DB >> 20385369

Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses.

Beom Su Kim1, Sung Tae Oh, Jeong Hwan Yook, Kab Choong Kim, Min Gyu Kim, Jun Won Jeong, Byung Sik Kim.   

Abstract

BACKGROUND: Gastric endocrine tumors are usually classified as 3 types of well-differentiated endocrine tumors (typical carcinoids or carcinoids) and poorly differentiated carcinomas (neuroendocrine carcinomas [NECs]).
METHODS: From 1993 to 2008, 97 patients (73 men and 24 women) were diagnosed with gastric neuroendocrine tumors at the Asan Medical Center.
RESULTS: Of the 45 patients with typical carcinoids, 37 underwent surgery (eg, endoscopic resection). Of the 52 patients with NECs, 43 underwent surgery (eg, radical gastrectomy). One patient died of recurrence of the typical carcinoids, whereas 26 patients with NECs died of related diseases (P < .05). The rates of survival and recurrence did not significantly differ by type of typical carcinoid (P > .05).
CONCLUSIONS: Regardless of the type, carcinoids that are not yet advanced can be effectively treated with minimal endoscopic or laparoscopic surgery. However, all NECs and advanced carcinoids should be treated with radical gastrectomy. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20385369     DOI: 10.1016/j.amjsurg.2009.10.028

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  16 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 2.  Debulking Surgery for Moderately Differentiated Neuroendocrine Gastric Carcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Iuliana Halmaciu; Ciprian Bolca; Adrian Neacsu; Dragos Cretoiu; Cristian Balalau; Camelia Diaconu; Laura Iliescu; Alexandru Filipescu; Cora Pop; Irina Balescu
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 3.  Endoscopic diagnosis and management of type I neuroendocrine tumors.

Authors:  Yuichi Sato
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 4.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  A clinical perspective on gastric neuroendocrine neoplasia.

Authors:  Ben Lawrence; Mark Kidd; Bernhard Svejda; Irvin Modlin
Journal:  Curr Gastroenterol Rep       Date:  2011-02

6.  Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute.

Authors:  Takeshi Kubota; Shigekazu Ohyama; Naoki Hiki; Souya Nunobe; Noriko Yamamoto; Toshiharu Yamaguchi
Journal:  Gastric Cancer       Date:  2012-01-18       Impact factor: 7.370

7.  Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome.

Authors:  Andrew Hanna; Caroline Kim-Kiselak; Rebecca Tang; David C Metz; Zhaohai Yang; Ronald DeMatteo; Douglas L Fraker; Robert E Roses
Journal:  Ann Surg Oncol       Date:  2021-06-13       Impact factor: 5.344

Review 8.  Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors.

Authors:  Sébastien Gaujoux; Alain Sauvanet; Jacques Belghiti
Journal:  Target Oncol       Date:  2012-08-25       Impact factor: 4.493

9.  Neuroendocrine carcinoma of the stomach: A case report.

Authors:  Sang Hyun Kang; Kwang Hee Kim; Sang Hyuk Seo; Min Sung An; Tae Kwun Ha; Ha Kyung Park; Ki Beom Bae; Chang Soo Choi; Sang Hun Oh; Young Kil Choi
Journal:  World J Gastrointest Surg       Date:  2014-04-27

10.  Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation.

Authors:  Tsutomu Namikawa; Toyokazu Oki; Hiroyuki Kitagawa; Takehiro Okabayashi; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.